Portada›Viernes 7 de noviembre de 2025

Biomédicas del NASDAQ ante la SEC, viernes 7 de noviembre de 2025

Los 78 documentos que 61 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← jueves 6 de noviembre de 2025 · lunes 10 de noviembre de 2025 →

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

1. BFRGBullFrog AI Holdings, Inc.424B5Nueva emisión de acciones con precioEDGAR
2. BNTCBenitec Biopharma Inc.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoDebilidad material en el control internotexto original ▸

   …sales, marketing, manufacturing and distribution requirements; • greater than expected expenses, expenses relating to litigation or strategic activities; • the impact of, and our ability to remediate, the identified material weakness in our internal controls over financial reporting; • our ability to satisfy our capital needs through increasing revenue and obtaining additional financing; and • the impact of local, regional and national…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …Form S-3 (File No. 333-277310) with the SEC registering up to $125 million of our common stock, debt securities, warrants, and units (the “February 2024 S-3 Shelf”). Subsequently, in October 2024, we entered into an open market sales agreement and filed a prospectus supplement related to an at-the-market offering of up to $75 million of our common stock registered under the February 2024 S-3 Shelf. On November 1, 2024, we filed a registration statement on Form S-3 (File No. 333-282957) with the SEC registering…
3. DRMADermata Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
4. GOVXGeoVax Labs, Inc.424B3Prospecto suplementario o de reventaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …and may not remain in business. We have received a going concern opinion from our auditors. We have received a "going concern" opinion from our independent registered public accounting firm, reflecting substantial doubt about our ability to continue as a going concern. Our consolidated financial statements contemplate that we will continue as a going concern and do not contain any adjustments that might result if we were unable to continue as a going concern. Our ability…

   En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸

   …share price, and certain corporate governance requirements. There can be no assurances that we will be able to continue to comply with the applicable listing standards. On July 31, 2025, the “Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …primarily from sales of our equity securities and from government grants and clinical trial assistance. During 2024, we closed four registered direct offerings of our Common Stock and warrants, as well as established the ATM Program (see footnote 6 to the consolidated financial statements included in this prospectus). Net proceeds to us from these offerings, after deducting commissions to the placement agent and sales agent, as applicable…
5. HYFTMindWalk Holdings Corp.424B5Nueva emisión de acciones con precioEDGAR
6. INKTMiNK Therapeutics, Inc.S-3Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …December 31, 2024 consolidated financial statements contains an explanatory paragraph that states that the Company has suffered recurring losses from operations and has a net capital deficiency that raises substantial doubt about the entity’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty. 25 Table of Contents $150,000,000 Common Stock Preferred Stock Warrants Debt…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …relates to the issuance and sale of up to $50,000,000 of our common stock, $0.00001 par value per share, from time to time through our sales agent, B. Riley Securities, Inc. (the “Sales Agent”). We have entered into an At Market Issuance Sales Agreement (the “ATM Sales Agreement”) with the Sales Agent relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the ATM Sales Agreement, we may offer…
7. RANIRani Therapeutics Holdings, Inc.S-3Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …audited our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company’s ability to continue as a going concern as described in Note 1 to the consolidated financial statements), as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial…
8. SCNXScienture Holdings, Inc.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …pursuant to Rule 424(b)(5) Registration No. 333-289198 Prospectus Supplement (To Prospectus dated August 8, 2025) Scienture Holdings, Inc. Up to $150,000,000 Common Stock Scienture Holdings, Inc. has entered into an Equity Distribution Agreement (the “ATM Sales Agreement”) with Maxim Group LLC (“Maxim”) dated September 19, 2025, relating to the sale of shares of our common stock, par value $0.00001 per share, offered by this prospectus supplement and the accompanying…
9. SNGXSOLIGENIX, INC.424B3Prospecto suplementario o de reventaEDGAR
10. SNGXSOLIGENIX, INC.424B3Prospecto suplementario o de reventaEDGAR
11. SNGXSOLIGENIX, INC.424B3Prospecto suplementario o de reventaEDGAR
12. COGTCogent Biosciences, Inc.S-3ASRCapacidad de emisión registradaEDGAR
13. GANXGain Therapeutics, Inc.S-3/ACapacidad de emisión registrada (enmienda)EDGAR
14. INABIN8BIO, INC.S-3Capacidad de emisión registradaEDGAR
15. PRMEPrime Medicine, Inc.S-3ASRCapacidad de emisión registradaEDGAR
16. QNRXQuoin Pharmaceuticals Ltd.S-3Capacidad de emisión registradaEDGAR
17. TCRTAlaunos Therapeutics, Inc.S-3/ACapacidad de emisión registrada (enmienda)EDGAR

Participaciones y control

1. IVVDInvivyd, Inc.SC 13D/ACambio en participación significativaEDGAR
2. LENZLENZ Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
3. NAMSNewAmsterdam Pharma Co N.V.SC 13D/ACambio en participación significativaEDGAR
4. SIONSionna Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

1. SHPHShuttle Pharmaceuticals Holdings, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
2. TNYATenaya Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
   En el documentoParada clínica impuesta por la FDAtexto original ▸

   …for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01 Other Events. The U.S. Food and Drug Administration (“FDA”) has placed a clinical hold on MyPEAKTM-1,Tenaya Therapeutics, Inc.’s (“Tenaya”) Phase 1b/2a clinical trial evaluating TN-201 in MYBPC3-associated hypertrophic cardiomyopathy, requesting an amendment to the protocol primarily to…
3. ALXOALX ONCOLOGY HOLDINGS INC8-KResultadosEDGAR
4. ALXOALX ONCOLOGY HOLDINGS INC10-QInforme trimestralEDGAR
   En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸

   …The Notice had no immediate effect on the listing of our common stock on the Nasdaq Global Select Market, subject to our compliance with the other listing requirements of Nasdaq. In September 2025, we received written confirmation from the Staff of Nasdaq that we had regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market, as the closing bid price of our common stock had been at $1.00 per share or greater for ten consecutive business days. Components…
5. ANIPANI PHARMACEUTICALS INC8-KResultadosEDGAR
6. ANIPANI PHARMACEUTICALS INC10-QInforme trimestralEDGAR
7. BFRIBiofrontera Inc.8-KNuevo acuerdo materialEDGAR
8. BNTCBenitec Biopharma Inc.8-KNuevo acuerdo materialEDGAR
9. BRNSBarinthus Biotherapeutics plc.8-KResultadosEDGAR
10. BRNSBarinthus Biotherapeutics plc.10-QInforme trimestralEDGAR
11. BTMDbiote Corp.10-QInforme trimestralEDGAR
    En el documentoDebilidad material en el control internotexto original ▸

    …procedures were not effective at a reasonable assurance level based on the prior material weakness that existed in our internal control over financial reporting as described below. Notwithstanding the identified material weakness, management, including our Chief Executive Officer and Chief Financial Officer, believes the unaudited condensed consolidated financial statements included in this Quarterly Report fairly present, in…
12. CELZCREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.10-QInforme trimestralEDGAR
13. CGCCanopy Growth Corp10-QInforme trimestralEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

    …61,707 19 17. SHARE CAPITAL CANOPY GROWTH Authorized An unlimited number of common shares and exchangeable shares (the “Exchangeable Shares”). (i) Equity financings On February 28, 2025, the Company established an at-the-market equity program that allowed it to issue and sell up to US$200,000 of common shares of the Company to the public from time to time at the Company's discretion (the “February 2025 ATM Program”) pursuant to an equity distribution…
14. CGCCanopy Growth Corp8-KResultadosEDGAR
15. COGTCogent Biosciences, Inc.10-QInforme trimestralEDGAR
16. CPIXCUMBERLAND PHARMACEUTICALS INC10-QInforme trimestralEDGAR
17. CRVOCervoMed Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

    …to finance its operations and pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. These conditions cause substantial doubt regarding the Company’s ability to continue as a going concern. The Company will continue to require additional financing to advance its current product candidates through clinical development, to develop, acquire or in-license other potential product candidates…

    En el documentoDebilidad material en el control internotexto original ▸

    …design and operation of our disclosure controls and procedures as of the end of the period covered in this report. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are ineffective due to the material weakness noted below in the subsequent paragraph. Material Weaknesses in Internal Control over Financial Reporting In connection with the audit of the Company’s consolidated financial statements for the years…
18. DRMADermata Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
19. DWTXDogwood Therapeutics, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

    …will be able to secure such additional sources of funds to support our operations, or, if such funds are available to us, that such additional financing will be sufficient to meet our needs. As a result, substantial doubt exists regarding our ability to continue as a going concern 12 months from the issuance of this Quarterly Report on Form 10-Q. Failure to secure the necessary financing in a timely manner and on favorable terms could have a material adverse effect on the Company…
20. ELDNEledon Pharmaceuticals, Inc.8-KResultadosEDGAR
21. ERNAErnexa Therapeutics Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

    …connection with preparing the accompanying condensed consolidated financial statements as of and for the three and nine months ended September 30, 2025, the Company’s management concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern because it does not expect to have sufficient cash or working capital resources to fund operations for the twelve-month period subsequent to the issuance date of these condensed consolidated financial…

    En el documentoContrasplit de accionestexto original ▸

    …2025, or any other period. Reverse Stock Split As approved by the Company’s stockholders at the Company’s Annual Meeting of Stockholders held on June 2, 2025 (the “2025 Annual Meeting”), the Company effected a reverse stock split of its common stock at a ratio of 1-for-15, as determined by the Company’s Board of Directors within the parameters approved by the Company’s stockholders (the “Reverse Stock Split”). The Reverse Stock…
22. EXELEXELIXIS, INC.8-KCambio en el consejo o la direcciónEDGAR
23. FDMT4D Molecular Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
24. GERNGERON CORP10-QInforme trimestralEDGAR
    En el documentoDebilidad material en el control internotexto original ▸

    …financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified a material weakness in our internal control over financial reporting. Specifically, management identified deficiencies in the design and operation of certain Information Technology General Controls, or ITGCs, related to…
25. GILDGILEAD SCIENCES, INC.10-QInforme trimestralEDGAR
26. GYREGYRE THERAPEUTICS, INC.8-KResultadosEDGAR
    En el documentoDesignación de terapia innovadora (breakthrough)texto original ▸

    …of pirfenidone, which demonstrated statistically significant fibrosis regression after 52 weeks of treatment in a pivotal Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC. Hydronidone received Breakthrough Therapy designation by the NMPA Center for Drug Evaluation in March 2021. Gyre Pharmaceuticals is also developing treatments for PD, RILI with or without immune-related pneumonitis, COPD, PAH and ALF/ACLF. In October 2023…
27. GYREGYRE THERAPEUTICS, INC.10-QInforme trimestralEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

    …in the name of the Company to Futu Network Technology Limited, the stock plan administrator of the 2023 Omnibus Incentive Sub-Plan for Chinese participants. 2024 ATM Program On November 27, 2024, Gyre entered into an Open Market Sale Agreement (the “ATM Agreement”) with Jefferies LLC (the “Sales Agent”) as sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of common stock with aggregate gross sales…
28. HALOHALOZYME THERAPEUTICS, INC.8-KOtros hechos relevantesEDGAR
29. IMMXImmix Biopharma, Inc.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

    …recurring losses from operations incurred since inception, the expectation of continued operating losses, and the need to raise additional capital to finance our future operations, we determined that there is substantial doubt about our ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. There is no assurance that funding will be available to us, will be obtained on terms favorable to us or will provide…

    En el documentoDebilidad material en el control internotexto original ▸

    …not effective as of September 30, 2025, due to the material weakness in internal control over financial reporting described below. 32 Material Weakness in Internal Controls Over Financial Reporting We identified a material weakness in our internal control over financial reporting that existed as of December 31, 2024, as discussed in greater detail in “Item 9A. Controls and Procedures” of the 2024 Form 10-K. A material weakness is…

    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

    …reimbursements under the grant agreement and approximately $3.4 million of remaining awarded funds are expected to be disbursed upon the achievement of certain milestones. On June 3, 2025, the Company entered into an At The Market Offering Agreement (the “June 2025 ATM Agreement”) with Citizens JMP Securities, LLC (“Citizens”) under which the Company may offer and sell, from time to time at its sole discretion, up to $50 million shares…
30. ISPCiSpecimen Inc.8-KCambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸

    …serve as Chief Executive Officer, Secretary, and Treasurer of the Company, effective immediately. Ms. Field will continue to serve as President of the Company. On the same date, Mr. Robert Bradley Lim stepped down as Chief Executive Officer, Secretary, and Treasurer of the Company and resigned as a member of the Board, effective immediately. Ms. Field, 41, has served as President since February 2025 and was previously a director from September…
31. KPRXKIORA PHARMACEUTICALS INC10-QInforme trimestralEDGAR
32. KPRXKIORA PHARMACEUTICALS INC8-KResultadosEDGAR
33. KZIAKAZIA THERAPEUTICS LTD20-FInforme anual (emisor extranjero)EDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

    …and may additionally incur other impairments to the business including reputational damage, which may materially and adversely affect the continuity of our business and our financial condition. There is substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing. The Company has limited cash resources and will periodically need additional funds to maintain the planned level of R&D activity. We expect to…

    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

    …opportunities to realise value from this product candidate. EVT801’s phase I clinical trial was completed and clinical study report is anticipated in 2026. 45 Table of Contents At-The-Market (ATM) Facility Kazia established an ‘at-the-market’ equity program (the “ATM facility”) with Oppenheimer & Co. Inc. (“Oppenheimer”), as sales agent, in April 2022. Under the ATM facility, Kazia may offer and sell through Oppenheimer up to an aggregate amount of US$50…
34. LGNDLIGAND PHARMACEUTICALS INC10-QInforme trimestralEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

    …Registration Statement”), which became automatically effective upon filing, covering the offering of common stock, preferred stock, debt securities, warrants and units. 32 On September 30, 2022, we also entered into an At-The-Market Equity Offering Sales Agreement (the “Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated (the “Agent”), under which we were able to, from time to time, sell shares of our common stock having an aggregate…
35. MBIOMUSTANG BIO, INC.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

    …implemented within one year after the date that the financial statements are issued and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that these unaudited financial statements are issued. In performing its evaluation, management excluded certain elements of its operating plan that cannot be considered…

    En el documentoContrasplit de accionestexto original ▸

    …continued listing on the Nasdaq Capital Market, namely, the minimum stockholders’ equity requirement (the “Equity Rule”) and the minimum bid price requirement (the “Bid Price Rule”). ​ On January 15, 2025, we effected a 1-for-50 reverse stock split. Thereafter, we were subsequently notified by the Nasdaq that we had regained compliance with the Bid Price Rule. ​ On February 10, 2025, we completed a best-efforts public offering for net proceeds of…

    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

    …price per share of common stock and accompanying Warrants) and will terminate on the five-year anniversary of commencement of sales in the Offering. ​ At-the-Market Offering On May 31, 2024, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with Wainwright (the “Manager”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock through or to the Manager…
36. MRVIMARAVAI LIFESCIENCES HOLDINGS, INC.10-QInforme trimestralEDGAR
37. MTVAMetaVia Inc.8-KOtros hechos relevantesEDGAR
38. NKTRNEKTAR THERAPEUTICS10-QInforme trimestralEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

    …stock, preferred stock, debt securities, warrants and or units having an aggregate public offering price of up to $300.0 million. In connection with the filing of the Shelf Registration Statement, we also entered into an equity distribution agreement (the ATM Sales Agreement) with Piper Sandler & Co. and BTIG, LLC, relating to the sale of our common stock having an aggregate offering price of up to $75.0 million (the ATM Shares). The sales of the ATM Shares will be made by…
39. NRCNRC HEALTH10-QInforme trimestralEDGAR
40. ONMDOneMedNet Corp8-KCambio en el consejo o la direcciónEDGAR
41. PEPGPepGen Inc.8-KCambio en el consejo o la direcciónEDGAR
42. PRMEPrime Medicine, Inc.8-KResultadosEDGAR
    En el documentoRecorte de plantilla o reestructuracióntexto original ▸

    …facility related expenses, offset by Prime Medicine’s strategic focus on advancing its in vivo liver franchise, deprioritization of its CGD program, and a reduction in R&D personnel resulting from the workforce reduction. •General and Administrative (G&A) Expenses: G&A expenses were $11.2 million for the three months ended September 30, 2025, as compared to $14.1 million for the three months ended September 30, 2024.…
43. PRMEPrime Medicine, Inc.10-QInforme trimestralEDGAR
44. RYTMRHYTHM PHARMACEUTICALS, INC.8-KOtros hechos relevantesEDGAR
    En el documentoFecha de decisión de la FDA (PDUFA)texto original ▸

    …20251106xex99d1.htm EX-99.1 Exhibit 99.1 Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity ­-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, November 7, 2025 – Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming…
45. SMMTSummit Therapeutics Inc.8-KOtros hechos relevantesEDGAR
    En el documentoDesignación de vía rápida (Fast Track)texto original ▸

    …by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery,…
46. SNGXSOLIGENIX, INC.10-QInforme trimestralEDGAR
47. SRZNSurrozen, Inc./DE8-KResultadosEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸

    …Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer On November 6, 2025, the board of directors of the Company appointed Andrew Maleki, age 36, to the position of Chief Financial Officer, effective November 12, 2025, to serve as the Company’s principal financial and accounting officer. From May 2021 to October 2025, Mr. Maleki led corporate development and program leadership at Lassen…
48. SRZNSurrozen, Inc./DE10-QInforme trimestralEDGAR
49. TKNOAlpha Teknova, Inc.10-QInforme trimestralEDGAR
50. XCUREXICURE, INC.8-KResultadosEDGAR
51. XCUREXICURE, INC.10-QInforme trimestralEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

    …stockholders; •our ability to raise the additional capital that is needed to fund our operations and our pursuit of strategic alternatives, particularly given our current lack of a revenue source and the substantial doubt about our ability to continue as a going concern; •our ability to remain listed on The Nasdaq Capital Market (“Nasdaq”), including the ability to maintain minimum stockholders’ equity and stock price, and comply with applicable governance requirements…

Juntas de accionistas

1. BIAFbioAffinity Technologies, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
2. CELUCelularity IncDEF 14AConvocatoria de junta de accionistasEDGAR
3. DCOYDecoy Therapeutics Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
4. ONMDOneMedNet CorpDEF 14AConvocatoria de junta de accionistasEDGAR
5. OVIDOvid Therapeutics Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …markets, complete corporate collaborations or partnerships, attract, retain and motivate employees and pursue other business opportunities integral to our growth and success. Effect of the Previously Approved Reverse Stock Split In addition to the number of authorized shares of Common Stock increasing to 315,000,000 if stockholders approve the Authorized Shares Amendment and the Certificate of Amendment is filed and becomes effective…
6. SCLXScilex Holding CoDEF 14AConvocatoria de junta de accionistasEDGAR

← jueves 6 de noviembre de 2025 · lunes 10 de noviembre de 2025 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.